4月8日，据CDE官网消息，广东瑞迪奥科技有限公司联合申请药品“锝[99mTc]肼基烟酰胺双链Ark肽注射液”，获得临床试验默示许可，受理号CXHL2400080。
公示信息显示，药品“锝[99mTc]肼基烟酰胺双链Ark肽注射液”适应症：本品系放射性诊断用药，拟定用于HER2阳性乳腺癌的诊断及鉴别诊断。
广东瑞迪奥科技有限公司药品申请临床试验默示许可获受理
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.